Worked Pediatric Dose Recommendation

From a Reference Exposure to a Pediatric Regimen

A pediatric dose recommendation is not simply an adult dose reduced in proportion to body weight. A defensible calculation starts with a specified exposure target, predicts the child’s clearance using a model that accounts for body size and maturation, and then checks whether the resulting dose can actually be administered within the applicable dose cap and formulation constraints.

The examples below use a hypothetical drug and hypothetical model parameters. They illustrate the calculation, not a regimen for any real patient. A model-based exposure match is only as credible as its assumptions, the data supporting the model, and the suitability of its target for the clinical context.

Model and assumptions: Assume the drug has linear pharmacokinetics over the relevant dose range, the model predicts apparent oral clearance $CL/F$ in L/h, and the target is $AUC_{0-24}$ in mg·h/L. For a total oral dose $D_{24}$ in mg over 24 hours, predicted exposure is $AUC_{0-24}=D_{24}/(CL/F)$. The hypothetical pediatric model is $$ \frac{CL_i}{F}=\left(\frac{CL_{70}}{F}\right)\left(\frac{WT_i}{70\ \mathrm{kg}}\right)^{0.75}M(PMA_i), \qquad M(PMA)=\frac{PMA^3}{PMA^3+55^3}, $$ where $WT_i$ is weight in kg, $PMA_i$ is postmenstrual age in weeks, and $CL_{70}/F=5.00$ L/h is the reference apparent clearance at 70 kg. The maturation function and its parameters are stipulated for these examples; they are not universal pediatric values. The calculation assumes the child is within the model’s supported population and that the target exposure is clinically appropriate.

For a child born at gestational age $G$ weeks and currently aged $a$ weeks, postmenstrual age is $PMA=G+a$. Chronological age alone does not determine maturation in this model. The function $M(PMA)$ increases toward 1 as postmenstrual age increases, representing lower clearance during immaturity relative to the reference mature value.

The apparent-clearance form incorporates oral bioavailability: under linear kinetics, $AUC=F D/CL=D/(CL/F)$. If the model instead provided clearance $CL$ and bioavailability $F$ separately, the dose equation would need to retain $F$. Do not mix a clearance estimate with an exposure equation that assumes apparent clearance.

Why the Dose Equation Works

Over a dosing interval at periodic steady state, the amount of drug entering the systemic circulation equals the amount eliminated during that interval. With linear clearance, the elimination rate is $CL$ times concentration. Integrating over the interval gives $CL \times AUC$ as the eliminated amount; the administered systemic amount is $F D$. Equating these quantities yields the exposure relationship.

CL \times AUC = F D \quad\Longrightarrow\quad AUC=\frac{F D}{CL}=\frac{D}{CL/F}.

For a 24-hour target, solve for the total daily dose:

D_{24,\mathrm{target}}=AUC_{0-24,\mathrm{target}}\times\frac{CL}{F}.

If the daily amount is divided into multiple doses, the equation still predicts $AUC_{0-24}$ from the total amount administered in 24 hours, provided the linear model assumptions hold. Dividing the dose can change peak and trough concentrations even when total daily exposure is unchanged. Therefore, exposure matching alone does not establish that a dosing interval is suitable.

Worked Example: A Feasible Regimen for a Young Child

Suppose a hypothetical adult reference regimen is 600 mg orally every 24 hours, and the reference apparent clearance is 5.00 L/h. A child is 5 years old, weighs 18.0 kg, and was born at 40 weeks’ gestation. The proposed target is the exposure associated with the reference regimen. Assume the drug is intended to be given every 24 hours, the daily dose cap is 250 mg, and the available liquid contains 20 mg/mL and can be measured in 0.25 mL increments.

1. Set the target exposure. The reference regimen implies $AUC_{0-24}=600/5.00=120$ mg·h/L. This is the hypothetical target used for the calculation.

2. Calculate postmenstrual age and maturation. Five years is approximately 260 weeks, so $PMA=40+260=300$ weeks. Then $M(300)=300^3/(300^3+55^3)=0.9939$.

3. Predict apparent clearance.

\frac{CL_i}{F} =5.00\left(\frac{18.0}{70}\right)^{0.75}(0.9939) \approx 1.794\ \mathrm{L/h}.

The estimate uses the stated model, including its 70 kg reference and maturation function; it is not a direct measurement of this child’s clearance.

4. Calculate and round the daily dose. $D_{24,\mathrm{target}}=120\times1.794=215.3$ mg/day. The formulation allows 5 mg increments because $20\ \mathrm{mg/mL}\times0.25\ \mathrm{mL}=5$ mg. A 215 mg daily dose is therefore administerable as $215/20=10.75$ mL once daily.

5. Check cap and achieved exposure. The 215 mg dose is below the 250 mg/day cap. Its predicted exposure is $215/1.794=119.8$ mg·h/L, approximately 0.2 mg·h/L (about 0.13%) below the 120 mg·h/L target. The proposed dose is a close exposure match under the assumptions, not proof that the model or target is appropriate for a real child.

When the Cap Blocks the Target

A calculated dose is not automatically an allowable dose. A cap may be specified per dose or per day, and its meaning must be checked before rounding. If the target dose exceeds a cap, calculating the exposure at the capped regimen makes the trade-off explicit. Do not silently exceed a cap to force the predicted exposure to the target.

Worked Example: An Immature Infant Whose Target Exceeds the Cap

Consider a hypothetical infant born at 40 weeks’ gestation, now 2 months old (approximately 8.7 weeks), weighing 5.00 kg. Use the same model and a target $AUC_{0-24}$ of 120 mg·h/L. Suppose the intended interval is every 12 hours, the cap is 30 mg/day, and the liquid is 10 mg/mL with 0.1 mL measurement increments.

1. Evaluate maturation. $PMA=40+8.7=48.7$ weeks, so $M(48.7)=48.7^3/(48.7^3+55^3)\approx0.4098$. This value is substantially below 1 in the stipulated model.

2. Estimate apparent clearance.

\frac{CL_i}{F} =5.00\left(\frac{5.00}{70}\right)^{0.75}(0.4098) \approx 0.2831\ \mathrm{L/h}.

3. Calculate the target amount and divide it. The target daily amount is $120\times0.2831=33.97$ mg/day. At a 12-hour interval, that corresponds to $33.97/2\approx16.98$ mg per dose. The formulation could represent 17 mg as 1.7 mL, but two such doses give 34 mg/day, above the 30 mg/day cap.

4. Apply the cap and calculate exposure. The capped regimen is at most 15 mg every 12 hours, or 30 mg/day. At 10 mg/mL this is 1.5 mL per dose, compatible with the stated measurement increment. Predicted exposure is $30/0.2831=106.0$ mg·h/L, about 14.0 mg·h/L (11.7%) below target. Under these stipulated constraints, the target cannot be reached without exceeding the cap. This is a reason to seek an appropriate clinical or protocol-level review, not to override the cap.

Formulation, Interval, and Exposure Checks

The calculation should end with the dose that can be delivered, not merely the unrounded mathematical result. For a liquid, convert milligrams to millilitres using the stated concentration, then verify that the measuring device supports the proposed volume. For a tablet, consider its strength and whether it can be divided as intended. After any rounding, recalculate exposure from the dose that would actually be given.

Worked Example: Dividing a Daily Amount and Checking a Tablet Strength

A hypothetical 12-year-old weighs 40.0 kg, was born at 40 weeks’ gestation, and has a target $AUC_{0-24}$ of 120 mg·h/L. For this example, stipulate a 12-hour interval; the stated clearance model does not predict the interval, and it is not derived from the AUC calculation. Available tablets permit doses in 50 mg increments, and the daily cap is 400 mg.

1. Calculate maturity and clearance. Approximate age as 624 weeks, giving $PMA=40+624=664$ weeks and $M(664)\approx0.9994$. Then

\frac{CL_i}{F} =5.00\left(\frac{40.0}{70}\right)^{0.75}(0.9994) \approx3.284\ \mathrm{L/h}.

2. Find the target daily amount and per-dose amount. $D_{24,\mathrm{target}}=120\times3.284=394.1$ mg/day. Dividing equally every 12 hours gives approximately $394.1/2=197.1$ mg per dose.

3. Select an available amount and verify it. The nearest 50 mg increment is 200 mg per dose, or 400 mg/day. This equals the stated cap and gives predicted exposure $400/3.284=121.8$ mg·h/L, approximately 1.8 mg·h/L (1.5%) above target. The daily amount is feasible under the stated cap and tablet increments. A real recommendation would also need to confirm that the interval and tablet use are appropriate.

This example also shows why the interval and total daily dose must be kept distinct. Under the stated linear model, 400 mg given as 200 mg every 12 hours has the same predicted daily AUC as 400 mg given in another division pattern. It does not follow that those patterns have the same peak, trough, tolerability, or clinical suitability.

Diagnostics, Alternatives, and Limitations

Before using a model-based recommendation, verify that each input and assumption is coherent. Useful checks include the following:

Units: weight must be in kg, apparent clearance in L/h, dose in mg, and exposure in mg·h/L. The dose–exposure equation should produce mg.
Age and maturation: confirm whether the model uses chronological age, gestational age, postmenstrual age, or another age measure. Do not substitute one for another without justification.
Model applicability: check whether the child’s age, weight, renal function, and other relevant characteristics fall within the population supporting the model. Extrapolation beyond that range can be unreliable.
Cap and administration: identify whether the cap applies per dose or per day, convert the selected dose to the actual formulation, and recalculate exposure after rounding.
Prediction diagnostics: compare the model’s predictions with relevant observations and inspect whether predictions show systematic error in age or weight subgroups. A plausible arithmetic result does not rule out model bias.

A weight-based regimen is simpler and may be appropriate when supported by evidence, but it can miss maturation-related clearance differences. Body-surface-area dosing is another size-based approach; it does not, by itself, represent this model’s explicit maturation function. A population-model approach combines specified covariates to predict clearance and target exposure, but depends on the model and its validated range. These approaches are alternatives to evaluate against the drug’s evidence and clinical context, not interchangeable formulas.

The principal limitation is that matching one AUC target does not guarantee an appropriate concentration profile or outcome. The calculation also assumes linear, time-invariant apparent clearance and a valid exposure target; altered absorption, nonlinearity, changing renal function, interacting drugs, or a poorly supported maturation model can undermine the result. When these assumptions are doubtful, the calculated regimen should not be treated as a definitive recommendation.

Common Mistake

Pitfall: “The target dose is 34 mg/day, so give 17 mg every 12 hours even though the cap is 30 mg/day.” This reasoning treats target attainment as more important than the stated constraint. The correction is to apply the cap, calculate the exposure under the capped regimen, and report that the target is not achieved within the allowed amount. The dose must not be silently raised to remove the shortfall.

A second frequent error is to round the calculated dose and then report the exposure from the unrounded amount. Always use the administerable dose in the final exposure check. Report the calculated target amount separately from the selected regimen, and ensure that any stated difference or percentage is consistent with the displayed numbers.

Key takeaway: A pediatric model-based recommendation links a reference exposure to a maturation- and weight-adjusted clearance estimate, then tests the actual rounded regimen against formulation and cap constraints. If those constraints prevent target attainment, state the limitation rather than implying that the target was met.

Check Your Understanding

Answer each question, then compare with the solutions below.

A hypothetical child has apparent clearance 2.00 L/h and a target $AUC_{0-24}$ of 90 mg·h/L. What total daily dose matches the target?
In the stated maturation function, what does a value of $M(PMA)$ below 1 do to predicted apparent clearance, all else equal?
A calculated daily amount is 180 mg, but the cap is 160 mg/day. What should be reported about target attainment?
Why can two regimens with the same total daily dose have similar predicted AUC but different peak and trough concentrations?

Solutions. (1) $90\times2.00=180$ mg/day. (2) It reduces predicted apparent clearance relative to the mature reference, because it multiplies the weight-scaled clearance by a factor below 1. (3) The capped regimen cannot deliver the calculated target amount; calculate its predicted exposure as $160/(CL/F)$ using the applicable clearance, report the resulting shortfall, and do not exceed the cap to force target attainment. (4) AUC depends on total dose under the linear model, whereas concentration fluctuations also depend on how the dose is divided and on the drug’s disposition over the interval.